Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study.
Rijksen BLT, Pos FJ, Hulshof MCCM, Vernooij RWM, Jansen H, van Andel G, Wijsman BP, Somford DM, Busstra MB, van Moorselaar RJA, Kaa CAH, van Leenders GJLH, Hamberg P, van den Berkmortel F, Fütterer JJ, Kiemeney LA, van Oort IM, Aben KKH. Rijksen BLT, et al. Among authors: hulshof mccm. Eur Urol Focus. 2021 Mar;7(2):332-339. doi: 10.1016/j.euf.2019.11.005. Epub 2019 Nov 17. Eur Urol Focus. 2021. PMID: 31748122 Review.
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Boevé LMS, et al. Among authors: hulshof mccm. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25. Eur Urol. 2019. PMID: 30266309 Clinical Trial.
Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors.
Jansen H, van Oort IM, van Andel G, Wijsman BP, Pos FJ, Hulshof MCCM, Hulsbergen-van de Kaa CA, van Leenders GJLH, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJA, Kiemeney LA, Aben KKH. Jansen H, et al. Among authors: hulshof mccm. Prostate Cancer Prostatic Dis. 2019 May;22(2):337-343. doi: 10.1038/s41391-018-0109-y. Epub 2018 Nov 14. Prostate Cancer Prostatic Dis. 2019. PMID: 30429595
187 results